Antisense oligomers for controlling candida albicans infections

Abstract

The present disclosure relates to the use of antisense oligomers in the treatment or therapy of Candida albicans infections. The present disclosure further describes the use of antisense oligomers in antisense therapy to inhibit the morphological transition of Candida albicans from yeast to filamentous form.

Description

technical field [0001] The present disclosure relates to the use of antisense oligomers in the treatment or therapy of Candida albicans infection. In particular, antisense oligomers were used to target specific genes involved in the morphological transformation of C. albicans from yeast to filamentous form. [0002] The present disclosure further describes the use of antisense oligomers in antisense therapy to inhibit the morphological transformation of Candida albicans from yeast to filaments. Background technique [0003] Candida species generally exist as commensal microorganisms, but they can also act as opportunistic pathogens with the ability to cause superficial and systemic infections. The incidence of Candida infection has increased significantly over the past few years due to the increasing number of elderly populations and immunocompromised patients, as well as the widespread use of indwelling medical devices. Candida albicans infection remains the most prevalen...

AI Technical Summary

Problems solved by technology

Despite the fact that ASOs for the control of bacterial growth have been developed over the past decade, antisense-based applications for the control of C. albicans) growth are sparse and underutilized [5]

Images